Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/513—Organic macromolecular compounds; Dendrimers
  • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
  • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/74—Synthetic polymeric materials
  • A61K31/765—Polymers containing oxygen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S977/00—Nanotechnology
  • Y10S977/70—Nanostructure
  • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S977/00—Nanotechnology
  • Y10S977/70—Nanostructure
  • Y10S977/788—Of specified organic or carbon-based composition
  • Y10S977/795—Composed of biological material
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S977/00—Nanotechnology
  • Y10S977/902—Specified use of nanostructure
  • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
  • Y10S977/915—Therapeutic or pharmaceutical composition

Definitions

• the present invention relates to new spherical particles of small dimensions, often less than 500 nm.
• the new particles of the present invention also called nanoparticles have the advantage of being able to circulate in the blood stream without any problem of size at the level of the capillaries and also have the advantage of being able to avoid the reticuloendothelial system.
• the invention also relates to the use of the new particles according to the invention in human or animal pharmacy.
• Nanoparticles that can be used for injection into the living system must be biocompatible. Thus all polymer systems not containing biodegradable or bioresorbable polymer chains are not acceptable for such injections. It is also preferable when using such systems that the degradation products are compatible with living organisms. To date only two types of polymers are suitable; these are lactic or glycolic polymers or mixed lactic-glycolic copolymers.
• the processes for preparing the nanoparticles can be divided into three types of process, the first consisting in polymerizing the monomers and in prprming the nanoparticles simultaneously, the other two consisting in dissolving the polymer and in forming the nanoparticles independently.
• the first type of process consists in carrying out a polymerization of a monomer in a solution so as to obtain a micellar dispersion of the polymer in the solution.
• This type of process is limited to monomers polymerizable in solution, it requires the elimination, after the polymerization step, of the polymerization catalyst, of low molecular weight oligomers, of the monomers and of surfactants necessary for the polymerization.
• the polymer obtained has a random molecular weight distribution.
• the second and third types of process consist in using preformed polymers, in solubilizing them in a solvent, in forming a precipitate or a dispersion from a solution of these polymers and of a non-solvent then in evaporating the solvent from way to recover them nanoparticles in the form of a colloidal suspension.
• the solvent solution is generally an organic solution of the polymer, the non-solvent solution is often an aqueous solution.
• the polymer is dissolved in an organic solvent miscible with water.
• this solution is mixed with the aqueous phase, the polymer insoluble in the aqueous phase / organic solvent mixture precipitates in the form of nanoparticles.
• the organic solvent containing the polymer, immiscible with water is emulsified in an aqueous phase and then the organic solvent is evaporated.
• the present invention relates to new nanoparticles avoiding the reticuloendothelial system based on polymers comprising a majority of degradable units and possibly containing no additional surfactant. They are obtained from a copolymer consisting of a majority of polylactic units and a minority of ethylene oxide and / or propylene oxide units. This copolymer corresponds for the majority of its units preferably to the following formula (I):.
• R represents in each of the ylene oxide units an identical or different group chosen from hydrogen or a methyl group
• R ' represents hydrogen or an alkyl group containing 1 to 4 carbon atoms, preferably a methyl group n is an integer between 20 and 1000 m is an integer between 10 and 1500
• the polylactic polymeric unit of this copolymer of formula (I) preferably has a molecular weight of between 700 and 100,000, the polyethylene oxide unit preferably has a molecular weight of between
• the polylactic polymeric unit has a molecular weight between 1,000 and 60,000
• the polyethylene oxide unit has a molecular weight between 1,000 and 6,000.
• the polylactic polymer is a polymer containing 50% of lactic units of configuration D (PLA50) and the polyalkylene oxide is a polyethylene oxide.
• This copolymer is preferably in a diblock form, that is to say that according to a practical manner of implementation, one starts with a monofunctional commercial polyethylene and / or propylene polyoxide of desired molecular weight, ie a molecular weight of between 1000 and 40,000 or else comprising 20 to 1000 ethylene or propylene oxide units, preferably comprising 20 to 150 ethylene oxide units or 20 to 100 propylene oxide units onto which lactide units are grafted until the desired molecular weight is obtained on the polylactic chain in the presence of an initiator such as in particular tin octoate.
• a monofunctional commercial polyethylene and / or propylene polyoxide of desired molecular weight ie a molecular weight of between 1000 and 40,000 or else comprising 20 to 1000 ethylene or propylene oxide units, preferably comprising 20 to 150 ethylene oxide units or 20 to 100 propylene oxide units onto which lactide units are grafted until the desired molecular weight is obtained on the polylactic chain in the presence
• polylactic blocks with a molecular weight of between 1,000 and 60,000 it is desirable to introduce between approximately 10 and 1,000 lactide units. It is very particularly preferred to use polyethylene oxide and / or polylactic propylene polyoxide copolymers whose chain contains between 10 and 150 lactic units.
• These new nanoparticles avoiding the reticuloendothelial system can also consist of a mixture of one or more pure polylactic polymer (s) and the copolymer of formula (I).
• This polylactic polymer is preferably a polymer comprising a 50/50 mixture of D and L isomers of lactic acid (PLA50).
• PVA50 lactic acid
• the final weight ratio in the polymer composition between the polyethylene ethylene and / or propylene unit and the polylactic units is preferably between 1 and 25% by weight. It is particularly preferred to use the composition obtained by mixing a polylactic polymer with a molecular weight of 60,000, a copolymer of formula (I) in which R represents hydrogen, n is equal to 48 and m is equal to 133 .
• the desired polylactic-ethylene and / or propylene polyoxide copolymer optionally in admixture with the polylactic polymer, is dissolved in a solvent or in a mixture of solvents, then the organic solution is poured into an aqueous solution, so as to cause the formation of nanoparticles by precipitation.
• no additional colloidal protective agent is optionally used.
• colloidal protective agent is understood to mean the surfactants of which the surface-active agents which promote the formation of colloids are part.
• the solvent or the mixture of solvents dissolving the copolymer is chosen from ketones such as acetone, cyclic ethers such as tetrahydrofuran, dioxanes; nitriles such as acetonitrile. We prefer to use acetone.
• the solubility of the copolymer in these solvents is preferably greater than 10 g / l.
• the aqueous solution can be pure water or a saline solution such as for example a buffer solution or also a glucose solution.
• the volume ratio between the aqueous solution and the solution of the copolymer is preferably between 0.5 and 10, and very particularly between 1 and 10.
• the amount of copolymer introduced into the solvent obviously depends on its solubility, but for better implementation of the invention, ie essentially to obtain an optimum yield of formed nanoparticles, an amount between 10 and 50 mg / ml is preferred.
• the polylactic polyethylene oxide of ethylene and / or propylene is dissolved in an ester, preferably in ethyl acetate, then the organic solution is poured into the aqueous solution.
• Nonoparticles are formed by the use of a microfluidizer.
• the solvent of the copolymer is then evaporated by heating the colloidal solution of nanoparticles above the boiling temperature of the solvent in the case where the elimination is carried out at atmospheric pressure or at a lower temperature if the evaporation is carried out under reduced pressure .
• the suspension of nanoparticles in water is filtered through a filter with a pore diameter of approximately 1 ⁇ m, so as to remove the aggregates and large particles.
• the yield of nanoparticles obtained generally exceeds 50%.
• nanoparticles can be carried out in the presence of a pharmaceutical active ingredient which can be introduced either in the solvent of the copolymer or in the precipitation solvent, it must preferably be soluble in the solvent of the polymer and not soluble in water , although it is always possible to form nanoparticles if the active principle is soluble in water, the yield will nevertheless be reduced.
• the nanoparticles obtained contain only the copolymer of formula (I) or the mixture of polylactic polymers and of copolymer of formula (I) and optionally an active principle if the precipitation is carried out in the presence of an active principle. They have an average diameter between 50 and 500 nm and preferably an average diameter between 50 and 250 nm.
• the nanoparticles obtained are used for injections into a living organism insofar as their essential advantage is to be able to avoid the reticuloendothelial system, thus their main application is found in human or animal pharmacy. Or for medical diagnosis.
• These products are injectable intramuscularly, subcutaneously, intraarterially, intravenously, intraorganically or intracavities without anaphylactic risk.
• Dl lactide 144 g polyethylene glycol 79.3 g are introduced into a 250 ml three-necked flask fitted with a paddle stirrer and an ascending cooler with circulation of dry nitrogen, the flask being heated by a regulated oil bath.
• the lactide is recrystallized the day before from ethyl acetate, then washed the same day with ethyl ether. It is dried under vacuum. All the reagents are loaded and then heated under slight reflux (110-114 ° C) for 5 hours and a half. The solvent is then removed under vacuum using a rotary evaporator (40 mm Hg - 100 ° C).
• the purification of the copolymer is carried out as follows:
• Example 1.1 is reproduced by introducing the following compounds: dl lactide 48.6 g polyethylene glycol 10 g stannous octoate 0.085 g toluene distilled 90 g after reaction 63.6 g of concentrate are obtained which are purified by the following method: in solution 40 g of concentrate in 200 g of dichloromethane until a homogeneous solution is obtained. This solution is poured slowly into 800 ml of water maintained between 55 and 60 ° C. The polymer precipitates and the dichloromethane is evaporated, the unreacted lactide remains in aqueous solution, the polymer is centrifuged and then dried in an oven under vacuum at 40 ° C. 35 g of polymer are obtained, the analysis of which by nuclear magnetic resonance makes it possible to determine the molecular weight. The latter is 9600 for the lactic chain and 2100 for the polyethylene oxide chain, which represents 133 lactic units and 48 ethylene oxide units.
• reaction medium is left to react for 5 hours at 140 ° C., at the end of the reaction, it is rapidly cooled and then part of the xylene is removed in vacuo.
• the polymer is dissolved in dichloromethane and precipitated with methanol. It is dried in a vacuum oven at 65 ° C.
• Each rat is injected with 400 ⁇ l of suspension, the rats are divided into batches of five, one for each concentration of polyethylene oxide.
• the kinetics of particle capture by the reticuloendothelial system is represented by plotting the radioactivity remaining in the plasma as a% of the radioactivity present in the plasma at the end of the perfusion as a function of time.
• the half-life of the particles as a function of the amount of polyethylene glycol introduced is indicated in the table below.
• the curves of radioactivity remaining in the plasma are plotted in the appendix.
• PLA50 9600 PEG 200 and 10 mg of poly (d, 1-lactic acid) of molecular weight 18000 labeled with C are used, which is dissolved in 1 ml of ethyl acetate. This solution is then dispersed using an ultraturrax in 10 ml of water. A coarse emulsion is obtained. It is then recycled for 2 minutes using a high pressure homogenizer type MICROFLUIDICS. The emulsion is freed from ethyl acetate using a rotary evaporator at a pressure of 50.5 cm of mercury at 20 ° C. The pseudolatex obtained consists of nanoparticles with an average diameter of 145 ⁇ 60 nm. The half-life of these nanoparticles in the blood is 1 hour.
• the aqueous phase is a solution of sodium cholate at 10 gl -1 in water. Diameter of the nanoparticles: 105 ⁇ 45 nm. Half-life: 0.5 hour.

Applications Claiming Priority (3)

Publications (1)

Family

ID=9414444

Family Applications (2)

Family Applications Before (1)

Country Status (16)

Families Citing this family (46)

Family Cites Families (7)

• 1991
  • 1991-06-28 FR FR9108041A patent/FR2678168B1/fr not_active Expired - Lifetime
• 1992
  • 1992-06-25 AT AT92401788T patent/ATE205718T1/de active
  • 1992-06-25 CA CA002102186A patent/CA2102186C/fr not_active Expired - Lifetime
  • 1992-06-25 DE DE69232062T patent/DE69232062T2/de not_active Expired - Lifetime
  • 1992-06-25 DK DK92401788T patent/DK0520888T3/da active
  • 1992-06-25 WO PCT/FR1992/000581 patent/WO1993000101A1/fr active IP Right Grant
  • 1992-06-25 ES ES92401788T patent/ES2162793T3/es not_active Expired - Lifetime
  • 1992-06-25 EP EP92401788A patent/EP0520888B1/de not_active Expired - Lifetime
  • 1992-06-25 MX MX9203353A patent/MX9203353A/es unknown
  • 1992-06-25 PT PT92401788T patent/PT520888E/pt unknown
  • 1992-06-25 EP EP92913934A patent/EP0591374A1/de active Pending
  • 1992-06-25 JP JP50136693A patent/JP3465260B2/ja not_active Expired - Lifetime
  • 1992-07-01 IE IE211092A patent/IE922110A1/en not_active IP Right Cessation
• 1993
  • 1993-12-01 NO NO934358A patent/NO306119B1/no not_active IP Right Cessation
  • 1993-12-27 FI FI935868A patent/FI109576B/fi not_active IP Right Cessation
• 1995
  • 1995-06-06 US US08/470,729 patent/US5683723A/en not_active Expired - Fee Related
• 2001
  • 2001-10-02 GR GR20010400869T patent/GR3036773T3/el unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events